Theoretical Studies of Flavone Acetic Acids

  • P. Sedda
  • C. Thomson


Flavone acetic acid (FAA) (NSC 347512) (LM975) is a novel antitumor agent synthesized by LIPHA pharmaceuticals (France) in 19841.


Neutral Molecule Natural Killer Cell Activity Contour Level Inactive Molecule Cytotoxic Effector Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    G. Atassi, P. Briet, J. J. Berthelon, and F. Collonges, Synthesis and antitumor activity of some 8-substituted-4-oxo-4H-1 benzopyrans, Eur. J. Med. Chem. 5:393 (1985).Google Scholar
  2. 2.
    R. Giavazzi, A. Garofalo, G. Damia, S. Garattini, and M. D’Incalci, Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts, Br. J. Cancer 57:277 (1988).PubMedCrossRefGoogle Scholar
  3. 3.
    G. P. Smith, S. B. Calveley, M. J. Smith, and B. C. Baguley, Flavone actic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours, Eur. J. Cancer Clin. Oncol. 23:1209 (1987).PubMedCrossRefGoogle Scholar
  4. 4.
    T. H. Corbett, M. C. Bissery, A. Wozniak, J. Plowman, L. Polin, E. Tapazoglou, J. Dieckman, and F. Valeriote, Activity of flavone acetic acid (NSC-347512) against solid tumors of mice, Invest New Drugs, 4:207 (1986).PubMedCrossRefGoogle Scholar
  5. 5.
    G. Pratesi, C. Manzotti, G. Damia, and M. D’Incalci, Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347512), Br. J. Cancer 58:144 (1988).PubMedCrossRefGoogle Scholar
  6. 6.
    M. C. Bibby, J. A. Double, and P. M. Loadman, Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512), Br. J. Cancer 58:341 (1988).PubMedCrossRefGoogle Scholar
  7. 7.
    L. M. Ching, and B. C. Baguley, Effect of flavone acetic acid (NSC 347512) on splenic cytotoxic effector cells and their role in tumour necrosis, Eur. J. Cancer Clin. Oncol. 25:821 (1989).PubMedCrossRefGoogle Scholar
  8. 8.
    L. M. Ching, and B. C. Baguley, Induction of natural killer cell activity by the antitumour compound flavone ascetic acid (NSC 347512), Eur. J. Cancer Clin. Oncol. 23:1047 (1987).PubMedCrossRefGoogle Scholar
  9. 9.
    L. M. Ching, and B. C. Baguley, Reduction of cytotoxic effector cell activity in colon 38 tumours following treatment with flavone acetic acid, Eur. J. Cancer Clin. Oncol. 25:1061 (1989).PubMedCrossRefGoogle Scholar
  10. 10.
    L. M. Ching, and B. C. Baguley, Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512), Eur. J. Cancer Clin. Oncol. 24:1521 (1988).PubMedCrossRefGoogle Scholar
  11. 11.
    J. L. Evelhoch, M. C. Bissery, G. G. Chabot, N. E. Simpson, C. L. McCoy, L. K. Heilbrun, and T. H. Corbett, Flavone acetic acid (NSC 347512) induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy, Cancer Res. 48:4749 (1988).PubMedGoogle Scholar
  12. 12.
    G. J. Finlay, G. P. Smith, L. M. Fray, and B. C. Baguley, Effect of flavone acetic acid on lewis lung carcinoma: evidence for an indirect effect, J. Natl. Cancer Inst. 80:241 (1988).PubMedCrossRefGoogle Scholar
  13. 13.
    R. L. Hornung, H. A. Young, W. J. Urba, and R. H. Wiltrout, Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon a/ß, J. Natl. Cancer Inst. 80:1226 (1988).PubMedCrossRefGoogle Scholar
  14. 14.
    R. H. Wiltrout, and R. L. Hornung, Natural products as antitumor agents: direct versus indirect mechanisms of activity of flavonoids, I, J. Natl. Cancer Inst. 80:1 (1988).CrossRefGoogle Scholar
  15. 15.
    L. S. Capolongo, G. Balconi, P. Ubezio, R. Giavazzi, G. Taraboletti, A. Regonesi, O. C. Yoder, and M. D’Incalci, Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 957), a new anticancer agent, Eur. J. Cancer Clin. Oncol. 23:1529 (1987).PubMedCrossRefGoogle Scholar
  16. 16.
    G. Damia, M. L. Zanette, C. Rossi, R. Mandelli, A. Ferrari, and M. D’ncalci, Dose-dependent pharmacokinetics of flavone acetic acid in mice, Cancer Chemother Pharmacol. 22:47 (1988).PubMedCrossRefGoogle Scholar
  17. 17.
    J. Cummings, D. J. Kerr, S. B. Kaye, and J. F. Smyth, Optimisation of a reversed-phase high-performance liquid chromatographic method for the determination of flavone acetic acid and its major human metabolites in plasma and urine, Journal of Chromatography 431:77 (1988).PubMedCrossRefGoogle Scholar
  18. 18.
    A. Gouyette, D. J. Kerr, S. B. Kaye, A. Setanoians, J. Cassidy, C. Bradley, G. Forrest, and M. Soukop, Flavone acetic acid:a nonlinear pharmacokinetic model, Cancer Chemother Pharmacol. 22:114 (1988).PubMedCrossRefGoogle Scholar
  19. 19.
    M. C. Bibby, J. A. Double, P. M. Loadman, and C. V. Duke, Reduction of tumor blood flow by flavone acetic acid:a possible component of therapy, J. Natl. Cancer Inst. 81:2126 (1989).CrossRefGoogle Scholar
  20. 20.
    R. B. Weiss, R. F. Greene, R. D. Knight, J. M. Collins, J. J. Pelosi, A. Sulkes, and G. A. Curt, Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512), Cancer Res. 48:5878 (1988).PubMedGoogle Scholar
  21. 21.
    D. J. Kerr, S. B. Kaye, J. Cassidy, C. Bradley, E. M. Rankin, L. Adams, A. Setanoians, T. Young, G. Forrest, M. Soukop, and M. Clavel, Phase I and pharmacokinetic study of flavone acetic acid, Cancer Res. 47:6776 (1987).PubMedGoogle Scholar
  22. 22.
    D. J. Kerr, T. Maughan, E. Newlands, G. Rustin, N. M. Bleehen, C. Lewis, and S. B. Kaye, Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma, Br. J. Cancer 60:104 (1989).PubMedCrossRefGoogle Scholar
  23. 23.
    C. Thomson, and D. Higgins, Electrostatic potential maps of flavone acetic acids: a new class of antitumor drugs, Int. J. Quantum chem. Ouantum Chemistry Symp. 22:697 (1988).CrossRefGoogle Scholar
  24. 24.
    C. Thomson, and P. Sedda, manuscript in preparationGoogle Scholar
  25. 25.
    M. J. S. Dewar, E. J. Zoebisch, E. F. Healy, and J. J. P. Stewart, AM1: a new general purpose quantum machanical model, J. Am. Chem. Soc. 107:3902 (1985).CrossRefGoogle Scholar
  26. 26.
    J. J. P. Stewart, MOPAC: a general molecular package; QCPE Bull. 455:43 (1983). (MOPAC-version 5 was suppied by Dr. Stewart).Google Scholar
  27. 27.
    G. G. Ferenczy, C. A. Reynolds, W. G. Richards, Semiempirical AM1 electrostatic potential and AMi electrostatic potential derived charges: a comparison with Ab-initio values, J. Comp. chemistry 11:1 (1989).Google Scholar
  28. 28.
    P. Politzer, and D. G. Truhlar, “Chemical Application of Atomic and Molecular Electrostatic Potential,” Plenum Press, New York and London, (1981).Google Scholar
  29. 29.
    C. Petrolongo, and J. Tomasi, The use of the electrostatic molecular potential in quantum pharmacology. I. Ab-initio results, Int. J. Quantum chem: Quantum Biology Symp. 2:181 (1975).Google Scholar
  30. 30.
    A. P. Mazurek, R. Osman, and H. Weinstain, Molecular determinants for recognition of triazole and tetrazole analogs of histamine at H2 receptors, Molecular Pharmacology 31:345 (1986).Google Scholar
  31. 31.
    A. F. Cuthbertson, and C. Thomson, Electrostatic potential of tumor promoters, J. Mol. Graphics 5:92 (1987).CrossRefGoogle Scholar
  32. 32.
    C. E. Edge, Ph. D thesis Univ. of St-Andfrews, U.K. (1987).Google Scholar
  33. 33.
    D. Higgins, Ph. D thesis Univ. of St-Andfrews, U.K. (1988).Google Scholar
  34. 34.
    M. L. Connolly, Molecular surface program, QCPE Bull. 1:429 (1981).Google Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • P. Sedda
    • 1
  • C. Thomson
    • 1
  1. 1.National Foundation for Cancer Research Project Department of ChemistryUniversity of St. AndrewsSt. Andrews, FifeScotland

Personalised recommendations